bluebird bio Revenue and Competitors

Claim your profile

Boston, MA USA

Location

$484M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • bluebird bio's estimated annual revenue is currently $53.6M per year.(i)
  • bluebird bio received $632.5M in venture funding in July 2018.
  • bluebird bio's estimated revenue per employee is $97,901
  • bluebird bio's total funding is $484M.
  • bluebird bio's current valuation is $612M. (January 2022)

Employee Data

  • bluebird bio has 548 Employees.(i)
  • bluebird bio grew their employee count by -22% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$13.8M73-39%$107.3MN/A
#2
$0.2M10%N/AN/A
#3
$3.1M2663%N/AN/A
#4
$29.6M12518%$351MN/A
#5
$15.8M84-18%$312.8MN/A
#6
$0.5M717%N/AN/A
#7
$235M269-43%$340.9MN/A
#8
$2.2M284%N/AN/A
#9
$0.6M10-9%N/AN/A
#10
$0.5M929%N/AN/A
Add Company

We are leading the gene therapy revolution. Our integrated product platforms encompass gene therapy, cancer immunotherapy and gene editing - providing us with the potential to treat, and hopefully cure, a broad range of serious diseases. We have a lot of energy, and it's not just the abundance of coffee that keeps us going. Find out what sparks our excitement and inspires us every day.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$484M

Total Funding

548

Number of Employees

$53.6M

Revenue (est)

-22%

Employee Growth %

$612M

Valuation

N/A

Accelerator

bluebird bio News

2022-04-20 - Bluebird bio's gene therapy Zynteglo could have high price ...

Bluebird bio's beta thalassemia gene therapy treatment Zynteglo might have some grounds to support an anticipated high price point,...

2022-04-17 - Stock Down 98% From Peak, Bluebird Bio Could Run Out Of Cash

Investment climate for publicly-traded biotech stocks poor; Despite recent layoffs, Bluebird Bio's cash position is weak; Bluebird Bio's revenue...

2022-03-30 - Bluebird bio cuts 30% of its workforce as gene therapy dreams ...

The multiple R&D, regulatory and commercialization setbacks have hit home for bluebird bio. Hoping to keep the business afloat, the gene therapy specialist...

2021-09-08 - bluebird bio : Secures $75 Million in Private Placement Equity Financing

bluebird bio, Inc. (NASDAQ: BLUE) announced today that it has entered into an agreement for a $75 million private placement of common stock and common stock equivalents with a healthcare investment fund selected as part of a competitive process. Proceeds from the financing will support ongoing R ...

2021-06-07 - BLUEBIRD BIO, INC. Bluebird bio : Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and β-Thalassemia Studies (Form 8-K)

bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and β-Thalassemia Studies CAMBRIDGE, Mass. - (BUSINESS WIRE) - June 7, 2021- bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical holds on the Ph ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$75M5553%N/A
#2
$106.6M5659%N/A
#3
$110.3M57013%N/A
#4
$156.8M5753%N/A
#5
$148.9M5844%N/A

bluebird bio Funding

DateAmountRoundLead InvestorsReference
2011-04-21$30.0MUndisclosedARCH Venture Partners, Third Rock VenturesArticle
2012-07-26$60.0MDDeerfield Partners, RA CapitalArticle
2013-06-03$60.0MDDeerfield Partners, RA CapitalArticle
2014-12-17$150.0MUndisclosedArticle
2015-06-25$575.0MBofA Merrill LynchArticle
2016-12-08$200.0MUndisclosedGoldman, Sachs & CoArticle
2017-06-28$350.0MUndisclosedGoldman Sachs & Co. LLCArticle
2017-12-14$600.0MUndisclosedMultipleArticle
2018-01-10$651.3MUndisclosedMultipleArticle
2018-07-25$632.5MUndisclosedMultipleArticle